# SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

> **NCT05704088** · PHASE4 · COMPLETED · sponsor: **Mansoura University** · enrollment: 100 (actual)

## Conditions studied

- SGLT2 INHIBITORS
- Lupus Nephritis
- BMD

## Interventions

- **DRUG:** Dapagliflozin tablet
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05704088
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-08
- **Primary completion:** 2024-01-08
- **Final completion:** 2024-01-08
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704088, "SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05704088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*